Background/Objectives: Osteoporosis-related fragility fractures are sentinel events that should trigger timely secondary prevention, yet post-fracture care remains inconsistent. Leveraging the NIH All of Us Research Program, we quantified initiation of osteoporosis pharmacotherapy after fragility fracture and explored associations by age, sex at birth, race, and ethnicity. Methods: Retrospective cohort study using All of Us Controlled Tier data (v8) included adults aged 45 to 100 years with an index fragility fracture using prespecified OMOP concept sets intended to capture fractures commonly associated with osteoporosis. A new-user design excluded participants with any osteoporosis pharmacotherapy in the 365 days before fracture; participants required at least 180 days of follow-up. The primary outcome was initiation of osteoporosis pharmacotherapy (bisphosphonates, denosumab, or anabolic agents) within 180 days. Secondary outcomes were completion of dual-energy x-ray absorptiometry (DXA) and bone-health laboratory testing within 180 days. Multivariable logistic regression estimated adjusted odds ratios (OR) for each outcome by age at fracture, sex at birth, race, and ethnicity. Results: Among 1492 eligible participants, 87 initiated pharmacotherapy within 180 days (5.83%). After adjustment, older age was associated with higher odds of initiation (OR 1.04 per year; 95% CI 1.02 to 1.05). Male participants had markedly lower odds of pharmacotherapy initiation (OR 0.20; 95% CI 0.11 to 0.37) and DXA screening (OR 0.22; 95% CI 0.15 to 0.32) compared with female participants. In exploratory adjusted models, we did not detect an independent association between race and pharmacotherapy initiation (White vs. Black/African American OR 1.01; 95% CI 0.49 to 2.09), while White participants had higher odds of DXA screening than Black/African American participants (OR 1.79; 95% CI 1.02 to 3.28). Conclusions: In this diverse national EHR-based cohort, initiation of osteoporosis pharmacotherapy after fracture was uncommon, highlighting a substantial secondary prevention gap. In exploratory adjusted models, male sex was associated with lower odds of pharmacotherapy initiation and DXA receipt, while White participants had higher odds of DXA receipt than Black participants. System-level post-fracture pathways, including fracture liaison services and EHR-based prompts, may improve equitable identification and treatment of osteoporosis for All of Us participants and their communities.
Background: Total wrist arthroplasty (TWA) is a motion-preserving alternative to wrist fusion for end-stage wrist arthritis, but concerns regarding long-term durability continue to limit broader use. Reported 10-year survivorship ranges from 70% to 80%, although real-world failure patterns remain poorly defined. Methods: Adverse events were reviewed for TWA devices submitted to the U.S. Food and Drug Administration Manufacturer and User Facility Device Experience database from January 1, 2015, to September 30, 2025. Reports were identified using the wrist arthroplasty device code and confirmed by manufacturer and implant name. Nonwrist devices and duplicate submissions were excluded. Event narratives were manually reviewed and assigned a primary failure mode using a predefined taxonomy. Reports lacking sufficient detail were excluded from analyses. Results: Among 313 unique reports with adequate information, loosening or component migration was the most common failure mode (37%), followed by dislocation or instability (18%) and infection (13%). Less common complications included tendon or nerve injury, polyethylene wear or metallosis, implant fracture, and periprosthetic fracture. Annual failure-mode reports peaked in 2022, with additional clustering in 2018 and 2019. Loosening/migration was most frequent in 2022, whereas dislocation/instability clustered in 2019. Manufacturer-year reporting was mostly by Stryker and Zimmer Biomet, though reports involved all manufacturer groups. Conclusions: These findings describe submitted adverse events rather than true failure rates and reflect the limitations of passive reporting. Contemporary TWA continues to encounter substantial mechanical and fixation-related complications, highlighting the need for improved implant design, refined technique, and stronger post-market surveillance.